229 related articles for article (PubMed ID: 25031270)
1. An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions.
Saito N; Qiao H; Yanagi T; Shinkuma S; Nishimura K; Suto A; Fujita Y; Suzuki S; Nomura T; Nakamura H; Nagao K; Obuse C; Shimizu H; Abe R
Sci Transl Med; 2014 Jul; 6(245):245ra95. PubMed ID: 25031270
[TBL] [Abstract][Full Text] [Related]
2. Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients.
Saito N; Yoshioka N; Abe R; Qiao H; Fujita Y; Hoshina D; Suto A; Kase S; Kitaichi N; Ozaki M; Shimizu H
J Allergy Clin Immunol; 2013 Feb; 131(2):434-41.e1-9. PubMed ID: 23111236
[TBL] [Abstract][Full Text] [Related]
3. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand.
Abe R; Shimizu T; Shibaki A; Nakamura H; Watanabe H; Shimizu H
Am J Pathol; 2003 May; 162(5):1515-20. PubMed ID: 12707034
[TBL] [Abstract][Full Text] [Related]
4. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Chung WH; Hung SI; Yang JY; Su SC; Huang SP; Wei CY; Chin SW; Chiou CC; Chu SC; Ho HC; Yang CH; Lu CF; Wu JY; Liao YD; Chen YT
Nat Med; 2008 Dec; 14(12):1343-50. PubMed ID: 19029983
[TBL] [Abstract][Full Text] [Related]
5. Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Abe R
J Dermatol; 2015 Jan; 42(1):42-8. PubMed ID: 25355273
[TBL] [Abstract][Full Text] [Related]
6. Exosomal microRNAs from PBMCs stimulated with culprit drugs enhanced keratinocyte cell death in Stevens-Johnson syndrome/toxic epidermal necrolysis.
Suthumchai N; Buranapraditkun S; Thantiworasit P; Rerknimitr P; Wongpiyabovorn J; Khanaraksombat S; Reantragoon R; Klaewsongkram J
J Eur Acad Dermatol Venereol; 2023 Jul; 37(7):1375-1384. PubMed ID: 36840393
[TBL] [Abstract][Full Text] [Related]
7. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
Chung WH; Hung SI
Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
[TBL] [Abstract][Full Text] [Related]
8. Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis.
Kinoshita M; Ogawa Y; Hama N; Ujiie I; Hasegawa A; Nakajima S; Nomura T; Adachi J; Sato T; Koizumi S; Shimada S; Fujita Y; Takahashi H; Mizukawa Y; Tomonaga T; Nagao K; Abe R; Kawamura T
Sci Transl Med; 2021 Jun; 13(600):. PubMed ID: 34193610
[TBL] [Abstract][Full Text] [Related]
9. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases.
Abe R
J Dermatol Sci; 2008 Dec; 52(3):151-9. PubMed ID: 18657400
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.
Hasegawa A; Abe R
F1000Res; 2020; 9():. PubMed ID: 32595945
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis.
Chung WH; Hung SI
J Dermatol Sci; 2012 Jun; 66(3):190-6. PubMed ID: 22541332
[TBL] [Abstract][Full Text] [Related]
12. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Tohyama M; Watanabe H; Murakami S; Shirakata Y; Sayama K; Iijima M; Hashimoto K
Br J Dermatol; 2012 Feb; 166(2):322-30. PubMed ID: 21936856
[TBL] [Abstract][Full Text] [Related]
13. [News in severe clinical adverse drug reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)].
Martínez-Cabriales SA; Gómez-Flores M; Ocampo-Candiani J
Gac Med Mex; 2015; 151(6):777-87. PubMed ID: 26581536
[TBL] [Abstract][Full Text] [Related]
14. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding.
French LE; Trent JT; Kerdel FA
Int Immunopharmacol; 2006 Apr; 6(4):543-9. PubMed ID: 16504917
[TBL] [Abstract][Full Text] [Related]
15. Upregulated RIP3 Expression Potentiates MLKL Phosphorylation-Mediated Programmed Necrosis in Toxic Epidermal Necrolysis.
Kim SK; Kim WJ; Yoon JH; Ji JH; Morgan MJ; Cho H; Kim YC; Kim YS
J Invest Dermatol; 2015 Aug; 135(8):2021-2030. PubMed ID: 25748555
[TBL] [Abstract][Full Text] [Related]
16. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature.
Ziemer M; Kardaun SH; Liss Y; Mockenhaupt M
Br J Dermatol; 2012 Mar; 166(3):575-600. PubMed ID: 22014091
[TBL] [Abstract][Full Text] [Related]
17. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Morel E; Escamochero S; Cabañas R; Díaz R; Fiandor A; Bellón T
J Allergy Clin Immunol; 2010 Mar; 125(3):703-10, 710.e1-710.e8. PubMed ID: 20132973
[TBL] [Abstract][Full Text] [Related]
18. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: frozen-section diagnosis.
Hosaka H; Ohtoshi S; Nakada T; Iijima M
J Dermatol; 2010 May; 37(5):407-12. PubMed ID: 20536645
[TBL] [Abstract][Full Text] [Related]
19. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Harr T; French LE
Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
[TBL] [Abstract][Full Text] [Related]
20. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a comparative review.
Yager JA
Vet Dermatol; 2014 Oct; 25(5):406-e64. PubMed ID: 24990284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
